Prevalence of Hemorrhoidal Disease in Patients with Non-Alcoholic Fatty Liver Disease: Immunological Risk Factors and Pathophysiological Mechanisms
Amanbayeva Sanobar Sirojidinovna1*, Sherbayeva Feruzaxon Anvarjon Qizi2, Mirzakamolova Fotima Adhamjon Qizi3 and Ziyayeva Muazzam Kupaysinovna3
1Department of Biochemistry and Pharmaceutics, 2Faculty of General Medicine, 3Faculty of Pediatrics, 4Department of Biochemistry and Pharmaceutics, Kokand University, Andijan Branch, Andijan, Uzbekistan
*Corresponding author
Abstract:
Non-alcoholic fatty liver disease (NAFLD) affects nearly one-third of adults worldwide and has become a major public health concern. Hemorrhoidal disease is another common condition that significantly affects quality of life. Although both disorders involve chronic inflammation and metabolic disturbances, their potential relationship has received little attention in the literature. The present study aimed to review the prevalence of hemorrhoidal disease among NAFLD patients and explore the immunological mechanisms that might link these conditions. In this study searched PubMed, Scopus, Web of Science, and Cochrane Library for relevant studies published between 2010 and 2024 using terms related to NAFLD, hemorrhoids, inflammation, and portal hypertension. NAFLD patients showed higher hemorrhoid prevalence than the general population. Key factors included elevated inflammatory cytokines (TNF-α, IL-6, IL-1β), gut-liver axis disruption, and subclinical portal hypertension. NAFLD and hemorrhoidal disease share common inflammatory pathways. Recognizing this link may help clinicians provide better care for patients with both conditions.
Keywords: NAFLD; Hemorrhoids; Inflammation; Cytokines; Gut-liver axis; Portal hypertension
References:
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2016;64(1):73-84.
- Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273.
- Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017-1044.
- Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012;18(17):2009-2017.
- Sandler RS, Peery AF. Rethinking what we know about hemorrhoids. Clin Gastroenterol Hepatol. 2019;17(1):8-15.
- Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease. Gut. 2020;69(9):1691-1705.
- Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513-1524.
- Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease. Hepatology. 2010;52(5):1836-1846.
- Cai J, Zhang XJ, Li H. The role of innate immune cells in nonalcoholic steatohepatitis. Hepatology. 2019;70(3):1026-1037.
- Wree A, McGeough MD, Peña CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med. 2014;92(10):1069-1082.
- Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19(29):5250-5269.
- Arab JP, Karpen SJ, Dawson PA, et al. Bile acids and nonalcoholic fatty liver disease. Hepatology. 2017;65(1):350-362.
- Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412-425.
- Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877-1887.
- Boursier J, Mueller O, Barret M, et al. The severity of NAFLD is associated with gut dysbiosis. Hepatology. 2016;63(3):764-775.
- Francque S, Laleman W, Verbeke L, et al. Increased intrahepatic resistance in severe steatosis. Lab Invest. 2012;92(9):1428-1439.
- Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts decompensation. Gastroenterology. 2007; 133(2): 481-488.
- Sun W, Cui H, Li N, et al. Comparison of fibrosis scores in NAFLD patients. Hepatol Res. 2016;46(9):862-870.
- Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017;23(1):1-12.
- Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1062-1079.
- Abenavoli L, Milic N, Di Renzo L, et al. Metabolic aspects of NAFLD patients. World J Gastroenterol. 2016;22(31):7006-7016.
- Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362-376.
- Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(4):474-485.
- Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of NAFLD. Metabolism. 2016;65(8):1038-1048.
- Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2017;28(4):250-260.
- Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of NAFLD. Annu Rev Physiol. 2016;78:181-205.
- Neuschwander-Tetri BA. Hepatic lipotoxicity and NASH pathogenesis. Hepatology. 2010;52(2):774-788.
- Noureddin M, Rinella ME. NAFLD, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015;19(2):361-379.
- Machado MV, Cortez-Pinto H. Non-invasive diagnosis of NAFLD: a critical appraisal. J Hepatol. 2013;58(5):1007-1019.
- Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis and long-term outcomes in NAFLD. Gastroenterology. 2015;149(2):389-397.
Download this article as 
How to cite this article:
Amanbayeva Sanobar Sirojidinovna, Sherbayeva Feruzaxon Anvarjon Qizi, Mirzakamolova Fotima Adhamjon Qizi and Ziyayeva Muazzam Kupaysinovna, R. K. 2026. Prevalence of Hemorrhoidal Disease in Patients with Non-Alcoholic Fatty Liver Disease: Immunological Risk Factors and Pathophysiological Mechanisms.
Int.J.Curr.Microbiol.App.Sci. 15(1): 176-180. doi:
https://doi.org/10.20546/ijcmas.2026.1501.021
Citations
National Academy of Agricultural Sciences (NAAS) 
